| Patent application number | Description | Published |
|---|
| 20080227841 | INTRAVESICAL APAZIQUONE ADMINISTRATION FOLLOWING TRANSURETHRAL RESECTION - Bladder cancer treatments include the intravesical administration of apaziquone immediately (e.g. within about 6 hours) following transurethral resection. | 09-18-2008 |
| 20080253994 | Methods and Compositions for Contributing to the Treatment of Cancers - Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ET | 10-16-2008 |
| 20080318846 | SENSITIZATION OF TUMOR CELLS TO RADIATION THERAPY THROUGH THE ADMINISTRATION OF ENDOTHELIN AGONISTS - Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ET | 12-25-2008 |
| 20090155206 | Methods, Compositions and Articles of Manufacture for Contributing to the Treatment of Cancers - Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET | 06-18-2009 |
| 20090163570 | BLADDER CANCER TREATMENT AND METHODS - Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments. | 06-25-2009 |
| 20090221615 | COMBINATION ANTI-CANCER AGENTS - The present disclosure relates to methods of treating cancer in mammals by administration of Lucanthone and at least one anti-metabolite. Pharmaceutical compositions and kits comprising Lucanthone and at least one anti-metabolite also are disclosed. | 09-03-2009 |
| 20110288143 | BLADDER CANCER TREATMENT AND METHODS - Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition. | 11-24-2011 |
| 20110288472 | BLADDER CANCER TREATMENT AND METHODS - Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, bladder cancer treatments include the intravesical administration of apaziquone immediately following transurethral resection. Also disclosed are therapeutic compositions comprising an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition. | 11-24-2011 |
